Skip to main content
Top
Published in: CEN Case Reports 2/2018

01-11-2018 | Case Report

Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys)

Authors: Masaru Sasaki, Tetsuhiko Yasuno, Kenji Ito, Akira Matsunaga, Satoshi Hisano, Yasuhiro Abe, Katsuhisa Miyake, Kosuke Masutani, Hitoshi Nakashima, Takao Saito

Published in: CEN Case Reports | Issue 2/2018

Login to get access

Abstract

Apolipoprotein (apo) E5 is a rare apoE isoform. The apoE5 (Glu3Lys) variant, which is caused by the substitution of lysine with glutamic acid at codon 3, has a relative frequency of 0.1% in Japan. Previous studies have reported that apoE5 (Glu3Lys) is associated with hyperlipidemia and cardiovascular diseases, but this isoform has higher LDL receptor-binding activity than that of normal apoE3. Nephropathy associated with apoE5 (Glu3Lys) alone has not yet been reported. We present a case of a 51-year-old man with nephrotic syndrome. On renal biopsy, three glomeruli showed segmental sclerosis with hypertrophy of podocytes and intracapillary marked infiltration of intraglomerular foam cells. These findings were compatible with focal segmental glomerulosclerosis (FSGS). The patient had mild diabetes mellitus and monoclonal gammopathy of undetermined significance, but there were no specific findings of nephrolopathy related to these diseases. Various factors are involved in the pathogenesis of FSGS, including dyslipidemia and apoE activity. Our findings suggest that abnormal lipid metabolism by ApoE5 (Glu3Lys) is involved in the onset of FSGS.
Literature
1.
go back to reference Matsunaga A, Sasaki J, Moriyama K, et al. Population frequency of apolipoprotein E5 (Glu3→Lys) and E7 (Glu244→Lys, Glu245→Lys) variants in western Japan. Clin Genet. 1995;48:93–9.CrossRef Matsunaga A, Sasaki J, Moriyama K, et al. Population frequency of apolipoprotein E5 (Glu3→Lys) and E7 (Glu244→Lys, Glu245→Lys) variants in western Japan. Clin Genet. 1995;48:93–9.CrossRef
2.
go back to reference Dong LM, Yamamura T, Yamamoto A. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts. Biochem Biophys Res Commun. 1990;168:409–14.CrossRef Dong LM, Yamamura T, Yamamoto A. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts. Biochem Biophys Res Commun. 1990;168:409–14.CrossRef
3.
go back to reference Dong LM, Yamamura T, Tajima S, Yamamoto A. Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3→Lys) and its binding to low density lipoprotein receptors. Biochem Biophys Res Commun. 1992;187:1180–6.CrossRef Dong LM, Yamamura T, Tajima S, Yamamoto A. Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3→Lys) and its binding to low density lipoprotein receptors. Biochem Biophys Res Commun. 1992;187:1180–6.CrossRef
4.
go back to reference Kodera H, Mizutani Y, Sugiyama S, et al. A case of lipoprotein glomerulopathy with ApoE Chicago and ApoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7(2):112–20.CrossRef Kodera H, Mizutani Y, Sugiyama S, et al. A case of lipoprotein glomerulopathy with ApoE Chicago and ApoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7(2):112–20.CrossRef
5.
go back to reference Takasaki S, Matsunaga A, Joh K, Saito T. A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I. CEN Case Rep. 2018;7(1):127–31.CrossRef Takasaki S, Matsunaga A, Joh K, Saito T. A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I. CEN Case Rep. 2018;7(1):127–31.CrossRef
6.
go back to reference Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2005;1:44–54.CrossRef Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2005;1:44–54.CrossRef
7.
go back to reference Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917–24.CrossRef Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917–24.CrossRef
8.
go back to reference Bruschi M, Catarsi P, Candiano G, et al. Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Kidney Int. 2003;63:686–95.CrossRef Bruschi M, Catarsi P, Candiano G, et al. Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Kidney Int. 2003;63:686–95.CrossRef
9.
go back to reference Saito T, Atkins RC. Contribution of mononuclear leucocoytes to the progression of experimental focal glomerular sclerosis. Kidney Int. 1990;37:1076–83.CrossRef Saito T, Atkins RC. Contribution of mononuclear leucocoytes to the progression of experimental focal glomerular sclerosis. Kidney Int. 1990;37:1076–83.CrossRef
10.
go back to reference Saito T, Ootaka T, Sato H, et al. Participation of macrophages in segmental endocapillary proliferation preceding focal glomerular sclerosis. J Pathol. 1993;170:179–85.CrossRef Saito T, Ootaka T, Sato H, et al. Participation of macrophages in segmental endocapillary proliferation preceding focal glomerular sclerosis. J Pathol. 1993;170:179–85.CrossRef
11.
go back to reference Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;15:359–65.CrossRef Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;15:359–65.CrossRef
12.
go back to reference Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein E2: A report of tree cases and review of the literature. Case Rep Nephrol Urol. 2013;3:128–35.CrossRef Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein E2: A report of tree cases and review of the literature. Case Rep Nephrol Urol. 2013;3:128–35.CrossRef
13.
go back to reference Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.CrossRef Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.CrossRef
Metadata
Title
Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys)
Authors
Masaru Sasaki
Tetsuhiko Yasuno
Kenji Ito
Akira Matsunaga
Satoshi Hisano
Yasuhiro Abe
Katsuhisa Miyake
Kosuke Masutani
Hitoshi Nakashima
Takao Saito
Publication date
01-11-2018
Publisher
Springer Japan
Published in
CEN Case Reports / Issue 2/2018
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-018-0331-4

Other articles of this Issue 2/2018

CEN Case Reports 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine